Anagram Therapeutics Inc.

Anagram Therapeutics is a clinical-stage biopharmaceutical company developing novel, orally delivered enzyme therapeutics for diseases caused by malabsorption syndromes and nutrient metabolism disorders. The company states it was founded by people with a proven track record in cystic fibrosis and rare diseases, with a near-term focus on exocrine pancreatic insufficiency and cystic fibrosis. Its pipeline features development programs associated with gastrointestinal, pancreatic and metabolic diseases, led by ANG003, a broad-spectrum recombinant digestive enzyme replacement therapy for exocrine pancreatic insufficiency.

Anagram Therapeutics was founded with the hope and determination to meaningfully improve the lives of people and families affected by rare and life-threatening diseases. The company states it was founded by people with a proven track record in cystic fibrosis and rare diseases. It is a clinical-stage biopharmaceutical company developing novel, orally delivered enzyme therapeutics for the treatment of diseases caused by malabsorption syndromes and nutrient metabolism disorders. Robert Gallotto is a co-founder and serves as President and Chief Executive Officer.

Focused on becoming the world's leading biopharmaceutical company developing breakthrough orally delivered enzymes for diseases that have a severe impact on patients' lives.

• ANG003

  Anagram's lead product for the treatment of exocrine pancreatic insufficiency (EPI); a new class of broad-spectrum recombinant digestive enzyme replacement therapy containing lipase for fat malabsorption, protease for protein malabsorption, and amylase for carbohydrate malabsorption.

1. 1Developing Novel Oral Enzyme Therapies for Malabsorption Diseases | Anagram Therapeuticsanagramtx.com
2. 2About Us | Anagram Therapeuticsanagramtx.com
3. 3Pipeline | Anagram Therapeuticsanagramtx.com
4. 4Leadership & Board | Anagram Therapeuticsanagramtx.com